The efficacy and safety of eltrombopag in 13 children with chronic immune thrombocytopenia / 中国医师进修杂志
Chinese Journal of Postgraduates of Medicine
;
(36): 1042-1045, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-955447
ABSTRACT
Objective:
To explore the efficacy and safety of eltrombopag in children with chronic primary immune thrombocytopenia (cITP).Methods:
The clinical data of 13 children with cITP in Children′s Hospital of Soochow University from July 2017 to December 2021 were retrospectively analyzed.Results:
Among 13 children with cITP, 7 males and 6 females, the median age was 5 years old, the median duration of illness was 2.2 years. The median therapy duration of eltrombopag was 5 months, the median maintenance dose was 25.0 mg/d, the median time to response was 4 weeks; complete response was in 5 cases, partial response was in 2 cases; 2 cases had skin disease, 1 case had arthralgia, 1 case had liver function abnormal, all complications did not cause serious impact.Conclusions:
Eltrombopag was an effective and safe therapeutic option for children with cITP.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Postgraduates of Medicine
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS